AMD Update 19: Combination Therapy May Be A “Game Changer” for Wet AMD

You may have seen or heard the news that a new drug, Fovista, from Ophthotech, when used in combination with Lucentis (and probably Avastin), has the potential to greatly improve the outcomes now experienced with anti-VEGF monotherapy. The results from a Phase 2b clinical study of 449 patients showed that the combination therapy resulted in a gain of 10.6 letters of vision on the ETDRS standardized chart at 24 weeks, a 62% increase over the 6.5-letter gain from Lucentis monotherapy.

Fovista is a novel anti-platlet-derived growth factor therapy. 

I did not understand the implication of this combined therapy (Read more...)

Full Story →